Empowering Health, One Device at a Time
At Geistek Pharmaceuticals, we are dedicated to pushing the boundaries of medical device innovation to improve patient outcomes and enhance healthcare practices worldwide. With a focus on delivering groundbreaking technologies, we strive to develop advanced medical devices that address critical healthcare needs and redefine standards of care.
Our passion for excellence drives us to collaborate with leading experts, clinicians, and healthcare professionals to identify unmet medical needs and develop innovative solutions. By harnessing the latest advancements in technology, engineering, and design, we create medical devices that are safe, effective, and user-friendly.
Geistek Pharmaceuticals is committed to improving patient care across a wide range of therapeutic areas. Our portfolio includes medical devices for cardiology, orthopedics, neurology, oncology, respiratory care, and many other specialties. Whether it’s diagnostic devices, surgical instruments, therapeutic equipment, or wearable technologies, we are dedicated to transforming healthcare through cutting-edge medical devices.
We understand the importance of rigorous testing and regulatory compliance in the development of medical devices. Our team of experts works closely with regulatory authorities to ensure that our devices meet the highest quality standards and adhere to strict safety guidelines. We prioritize patient safety and efficacy in all our endeavors.
In addition to developing innovative medical devices, Geistek Pharmaceuticals is committed to providing comprehensive support and training to healthcare professionals. We offer training programs and educational resources to ensure that medical practitioners are equipped with the knowledge and skills necessary to utilize our devices effectively and provide the best possible care to their patients.
At Geistek Pharmaceuticals, we believe in the power of collaboration and partnerships to drive medical device innovation. We actively seek collaborations with research institutions, universities, and industry leaders to foster knowledge exchange, share expertise, and accelerate the development of cutting-edge technologies.
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
